Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study

Autor: Felipe de Arriba de la Fuente, Mercedes Gironella Mesa, Miguel Teodoro Hernández García, Juan Alonso Soler Campos, Susana Herráez Rodríguez, María José Moreno Belmonte, Teresa Regueiro López, Miriam González-Pardo, María Casanova Espinosa, on behalf of the CARINAE Study Investigators

Publikováno v: Pharmaceuticals, Vol 17, Iss 10, p 1272 (2024)

Real-world evidence on the impact of monoclonal antibodies as first-line treatment in Spain is limited. This observational, retrospective and prospective, multicenter, descriptive study included 117 transplant-ineligible newly diagnosed multiple myel

Externí odkaz: https://doaj.org/article/a93039e76ef142c7b0c2c28ae9aa25dd

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

Autor: María-Victoria Mateos, Miguel-Teodoro Hernández, Carlos Salvador, Javier de la Rubia, Felipe de Arriba, Lucía López-Corral, Laura Rosiñol, Bruno Paiva, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prosper, Javier López, José-María Arguiñano, Joan Bladé, Juan-José Lahuerta, Jesús San-Miguel

Publikováno v: European journal of cancer (Oxford, England : 1990)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

[Background]: Smoldering multiple myeloma (SMM) is a heterogeneous disease in terms of progression to myeloma (MM), but its standard of care continues to be observation. [Methods]: The QuiRedex phase 3 trial initiated in 2007 included 119 high-risk p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40680cde6c9a13405fd41a802603917b
https://doi.org/10.1016/j.ejca.2022.07.030

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Autor: Veronica Gonzalez-Calle, Paula Rodriguez Otero, Beatriz Rey-Bua, Javier De La Rubia, Felipe De Arriba, Valentin Cabañas, Esther González Garcia, Enrique M. Ocio, Cristina Encinas, Alexia Suarez Cabrera, Joan Bargay, Joaquin Martinez Lopez, Marta Sonia Gonzalez, Jose Angel Hernandez-Rivas, Laura Rosiñol, Miguel-Teodoro Hernández, Bruno Paiva, Maria Teresa Cedena Romero, Noemi Puig, Juan-José Lahuerta, Joan Bladé, Jesús San-Miguel, Maria-Victoria Mateos

Publikováno v: Blood. 140:7286-7288

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a77f7df531a3ef084c2c0fd2b23a8eda
https://doi.org/10.1182/blood-2022-162584

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

Autor: Laura Notarfranchi, Anastasiia Zherniakova, Marta Lasa, Noemi Puig, María Teresa Cedena, Joaquin Martinez-Lopez, María José Calasanz, Diego Alignani, Leire Burgos, Irene Manrique, Yi-Ju Huang, Jochen Fracowiak, Clara Gomez, Felipe De Arriba, Paula Rodríguez-Otero, Luis Palomera, Anna Sureda, Maria Esther Clavero Sanchez, Miguel Angel Alvarez, Angela Ibanez Garcia, Miguel-Teodoro Hernández, Albert Perez, Ana Pilar Gonzalez, Enrique M. Ocio, Juan Flores-Montero, Alberto Orfao, Juan Jose Lahuerta, María-Victoria Mateos, Laura Rosiñol, Joan Bladé Creixenti, Jesús San-Miguel, Bruno Paiva

Publikováno v: Blood. 140:2095-2097

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::497fe879e685aa1394820d05b40b32dc
https://doi.org/10.1182/blood-2022-167382